AMRN and GSK Related Headlines
Go Back- Amarin (AMRN) Lower as Competitor Omthera Pharma (OMTH) Files IPO
- Amarin (AMRN) Weaker as Analyst Questions Vascepa's Superiority over Lovaza
- Amarin (AMRN) Ramps as BASF's Pronova Takeover Highlights Value
- Another Case Made for Amarin's (AMRN) Vascepa Missing NCE Status
- Amarin Corporation plc (AMRN) Ramps on Lovaza News
